This week we highlight the United States Food and Drug Administration’s approval of an insulin biosimilar and their granting of its status as interchangeable with the name brand drug. This promises significant savings for diabetic patients who often face financial hardships because of the cost of care. We also look at an artificial intelligence tool for ... READ MORE >
Life Sciences
The life sciences sector comprises some of the middle market’s fastest-growing companies. Whether developing life-saving new drugs or robotic components for surgery, this vibrant sector is a hotbed of innovation.
5 things to know in life sciences: Week of July 19
This week, we explore an innovative artificial intelligence app used to treat mental health issues. We consider opportunities related to investments in women’s health. We also look at a few pharma giants, including two with a commitment to supply COVID-19 vaccines to Africa and one with a series of big wins and losses in its second-quarter earnings ... READ MORE >
5 things to know in life sciences: Week of July 12
The medical devices sector is booming with activity as evidenced by the 114% year-over-year increase in industry-funded medical devices trial starts for the period of January through May. This week, we explore new technologies contributing to the medical devices boom, including a miniature surgical robot for needle-based procedures and new magnetic resonance ... READ MORE >
Drug pricing and health care innovation could benefit from Biden’s latest executive order
On July 9, President Biden issued an executive order on promoting competition in the American economy that could have significant ramifications for health care systems. The order indicates that the pace of business consolidation has accelerated and that “in over 75% of U.S. industries, a smaller number of large companies now control more of the business ... READ MORE >
5 things to know in life sciences: Week of June 28
Diabetes effects more than 10% of the U.S. population and brings with it the risk of serious complications, high health care costs and daily difficulties for patients that are afflicted with it. This week we look at the potential of using an old drug to help people with type 1 diabetes as well as the promise of a common tool used for type 1 patients to now ... READ MORE >
5 things to know in life sciences: Week of June 21
Deep brain stimulation (DBS) is a remarkable tool where a small device is implanted in the body with leads carefully placed at critical spots in the brain. The tool can help manage symptoms of some neurodegenerative diseases. Now, a new generation of devices from Medtronic offers additional tools to patients and doctors. We also look at remote laboratories, ... READ MORE >
5 things to know in life sciences: Week of June 14
Given the high volume of mergers and acquisitions in life sciences, changes in the leadership and focus of the Federal Trade Commission will be closely watched in the coming months as scrutiny could shift to the technology industry. We examine the possible impact below. We also look at CureVac’s COVID-19 vaccine trial results, how events at a plant in New ... READ MORE >
5 things to know in life sciences: Week of June 7
The U.S. Food and Drug Administration’s approval of the Alzheimer’s drug, aducanumab, ushered in both a likely blockbuster for developer Biogen and sparked a debate both within the biopharma industry and among health care providers. We also look at a major medical device acquisition, investment in synthetic biology, a White House report on supply chain risk, ... READ MORE >
5 things to know in life sciences: Week of May 31
Recruiting and retaining patients for clinical trials is one of the most intractable problems facing clinical research organizations and biopharma companies. CVS thinks that its thousands of retail locations could be the answer. We also look at Food and Drug Administration-approved video games, tracking patients using radar, drug manufacturing in the United ... READ MORE >
5 things to know in life sciences: Week of May 24
Over the past year, there has been a simmering dispute between hospitals and pharmaceutical companies over the 340B drug pricing program. This week, the United States Department of Health and Human Services weighed in strongly on the side of the hospitals. We also look at the discussion at the World Trade Organization on waiving intellectual property ... READ MORE >